Bibliographic Info
GuidelineWHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents.
Year of Publication2022
Issuing InstitutionWHO
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Very low
In children with multidrug- or rifampicin-resistant TB (MDR/RR-TB) aged below 6 years, an all-oral treatment regimen containing bedaquiline may be used.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Year2022
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year2025
InstitutionWorld Health Organization